Back to mobile site

Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)

June 27, 2024 7:53 AM EDT Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $214.00 price target on Moderna (NASDAQ: MRNA).The analyst commented, "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login